Introduction {#S1}
============

Classically, it is believed that adaptive helper T (T~H~) cells underlie the pathogenesis of multiple inflammatory skin disorders such as atopic dermatitis (AD) ([@R3]) and psoriasis ([@R37]). Unique cytokine profiles distinguish T~H~ cells into different subsets and define their effector functions. For example, T helper type 2 (T~H~2) cells produce hallmark type 2 cytokines IL-4, IL-5 and IL-13 are believed to underlie the pathogenesis of AD ([@R4]). In contrast, T helper type 17 (T~H~17) cells that produce IL-17 and IL-22 contribute to the development and progression of psoriasis ([@R26]). Traditionally, immunosuppressive therapeutics for the treatment of AD (e.g., calcineurin inhibitors) and psoriasis (e.g., methotrexate) are thought to broadly inhibit the function of these T~H~ cell subsets. However, recent studies suggest that previously unrecognized innate immune cells may regulate T~H~ cells in the skin and have direct contributions to the development of pathologic skin inflammation. Specifically, innate lymphoid cells (ILCs) have emerged as key players in the pathogenesis of multiple inflammatory skin disorders. This review will focus on the recent advances in our understanding of how ILCs drive skin inflammation and how they may differentially respond to tissue-specific cytokines and factors. We highlight recent studies that reveal how ILCs are regulated and discuss the therapeutic potential of targeting ILCs in the context of skin inflammation.

Definition of Innate Lymphoid Cell Subsets {#S2}
==========================================

ILCs are part of a family of innate immune cells that are derived from a common lymphoid progenitor and their development is partially or completely dependent on the common γ-chain (γc or CD132), IL-7, Notch and the transcription factor Inhibitor of DNA binding 2 (Id2) ([@R29]). More recent studies indicate that multiple ILC lineages are also dependent on the transcriptional repressor PLZF, while others (e.g., natural killer cells and lymphoid tissue inducers) are not ([@R6]). Further, all ILC subsets have also been shown to arise from a common lineage-negative (Lin^−^) Id2^+^ CD127^+^ CD25^−^ α4β7^+^ c-Kit^+^ precursor ([@R6]; [@R23]). ILCs are currently categorized into three distinct populations on the basis of their developmental requirements, transcription factor expression profile and/or expression of effector cytokines ([Figure 1](#F1){ref-type="fig"}): group 1 ILCs (ILC1s) are T-bet-dependent IFN-γ- and TNF-α-producing ILCs; RORα-dependent, TCF-1-dependent and GATA3-expressing group 2 ILCs (ILC2s) produce IL-4, IL-5 and IL-13; and RORγt-dependent group 3 ILCs (ILC3s) produce IL-17A and/or IL-22 ([@R49]). These ILC groups are analogous to the previously described IFN-γ and TNF-α-producing T~H~1, IL-4-, IL-5- and IL-13-producing T~H~2 and IL-17- and IL-22-producing T~H~17 CD4^+^ T~H~ cell subsets. However, although ILCs appear to have parallel functions to adaptive CD4^+^ T cells, they are unique in that they respond to innate signals in the absence of antigen-specificity and have distinct phenotypic and functional profiles.

Although similar to T~H~ cell subsets in their cytokine profile, ILCs are distinguished from the common cell lineages in that they do not express cell lineage (Lin) markers associated with T cells, B cells, DCs, macrophages and granulocytes but express CD25 (IL-2Ra), CD90 (Thy1 Ag) and CD127 (IL-7Ra) ([@R51]). Further, ILC2s can be readily identified by their expression of the receptor for IL-33 (IL-33R or T1/ST2 in mice or ST2 in humans). Different subsets of ILCs promote either tissue homeostasis or detrimental inflammatory processes at multiple epithelial barrier surfaces. Further, these cells have been implicated in a variety of different disease states including allergy, autoimmunity, cancer, infection and obesity ([@R15]; [@R22]; [@R31]; [@R38]; [@R48]). The roles of ILCs in various disease states and at other barrier surfaces have been covered extensively elsewhere ([@R11]; [@R16]; [@R25]; [@R33]; [@R48]). However, the diverse functional properties of ILCs in the skin remain less well defined. Therefore in this review we will focus primarily on the emerging role of ILCs in skin health and disease. First, we will introduce ILC2s given that multiple groups have defined their contribution to AD. Second, we will highlight recent studies identifying skin ILC3s and their role in psoriasis. Finally, we will briefly outline the function of ILC1s and their potential role in skin inflammation.

ILC2s and Atopic Dermatitis {#S3}
===========================

ILC2s were originally identified in the gut and associated lymphoid tissues and found to contribute to immunity to helminth parasites in the absence of the adaptive immune system ([@R9]; [@R10]; [@R34]; [@R36]; [@R40]; [@R46]). In addition to being distinguished by their expression of the effector type 2 cytokines IL-5 and IL-13, ILC2s also express IL-33R ([@R22]). Subsequent studies showed that ILC2s play key roles in airway hyper-reactivity ([@R5]) and epithelial tissue repair in the lung ([@R32]) in mice and chronic rhinosinusitis in humans ([@R28]; [@R30]). These early studies demonstrated that ILC2s were predominantly regulated by the epithelial cell-derived cytokines IL-25 and IL-33 ([@R33]).

When ILC2s were first identified in both murine ([@R21]; [@R43]) and human skin, they were also found to be highly enriched in lesional skin of patients with AD ([@R21]). Adaptive CD4^+^ T~H~2 cells that produce the effector type 2 cytokines IL-4, IL-5 and IL-13 are classically considered the main contributors to the pathogenesis of AD. It is believed that type 2 inflammation underlies acute to subacute AD which manifests histologically as a combination of irregular acanthosis (epidermal thickening), spongiosis (interepidermal edema) and superficial perivascular inflammation in the dermis composed predominantly of lymphocytes and histiocytes with occasional neutrophils and eosinophils. Strikingly, ILC2s that produce IL-5 and IL-13 were found to be both necessary and sufficient for the development of AD-like disease in a mouse model ([@R21]; [@R43]). Further, in contrast to the previously ascribed roles of IL-25 and/or IL-33 in the gut and lung, proinflammatory skin ILC2s were found to be dependent on another epithelial cell-derived cytokine called thymic stromal lymphopoietin (TSLP) ([@R21]). Beyond TSLP, a more recent study showed that transgenic overexpression of IL-33 under a keratin 14 promoter is sufficient to induce AD-like disease in association with the accumulation of ILC2s ([@R18]). In addition to IL-33, Salimi *et al.* found that skin ILC2 responses demonstrate dependence on IL-25, IL-33 and and/or TSLP depending on the mouse strain employed ([@R45]). Taken together, these studies identified a previously unrecognized role for skin ILC2s in the development of AD-like disease and their diverse mechanisms of regulation.

Similar to murine ILC2s, human skin ILC2s express IL-33R ([@R21]) as well as chemoattractant receptor-homologous molecule expressed on T~H~2 cells (CRTH2) ([@R45]; [@R56]). Xue *et al.* isolated CRTH2^+^ human skin ILC2s and showed that they migrate in response to the CRTH2 ligand prostaglandin D~2~ (PGD~2~) ([@R56]). Additionally, they express skin-homing receptors such as cutaneous lymphocyte antigen (CLA), CCR4 and CCR10, and are activated by IL-33 to produce the type 2 cytokines IL-5 and IL-13 ([@R45]; [@R52]). In terms of regulation, Salimi *et al.* found that IL-25 or TSLP alone did not directly activate healthy human skin ILC2s but significantly potentiated the effects of IL-33 ([@R45]). In contrast, Teunissen *et al.* found that TSLP alone was sufficient to activate expanded skin ILC2s and this effect was further enhanced by the addition of IL-25. ([@R52]). Therefore, the key epithelial cell-derived cytokines that regulate human skin ILC2s remain to be fully clarified in future studies. Notably, lesional AD skin from patients demonstrated increased expression of IL-17Rb (IL-25R), IL-33R and TSLP receptor (TSLPR) on ILC2s ([Figure 1](#F1){ref-type="fig"}) ([@R45]). These findings provoke the question as to whether activated human skin ILC2s in lesional AD skin respond differently to IL-25, IL-33 and/or TSLP than ILC2s derived from healthy control skin. Addressing this question may help to distinguish the relative importance of these cytokines in the context of established disease and the therapeutic potential of targeting them.

In addition to epithelial cell-derived cytokines, ILC2s are also activated by IL-2 and express the receptor for IL-7, indicating that they also respond to other stromal and hematopoietic cell-derived cytokines ([@R43]). More recently, ILC2s were found to express IL-4Rα ([@R1]) and respond to basophil-derived IL-4 by increasing the production of the chemokine CCL11 as well as effector cytokines IL-5, IL-9 and IL-13 ([@R35]). Along these lines, we recently identified that basophil-derived IL-4 critically regulates ILC2 proliferation in the context of AD-like inflammation (unpublished data). Taken together, these studies suggest that a variety of cytokines, chemokines and/or lipid mediators can differentially regulate the activation, migration, proliferation and effector function of ILC2s.

Beyond cytokine-mediated regulation, E-cadherin has been found to directly inhibit the effector cytokine production of human skin ILC2s, possibly via binding cell surface KLRG1 ([@R45]). Given that E-caderin is known to be downregulated in lesional AD skin ([@R53]), this may be a key upstream mechanism by which loss of epithelial adhesion molecules in the context of skin barrier dysfunction leads to dysregulated ILC2 responses in AD ([Figure 2](#F2){ref-type="fig"}). Indeed, these studies found that shRNA-mediated knockdown of filaggrin, a key skin barrier protein that is diminished in AD, results in loss of E-cadherin expression ([@R45]). Collectively, these studies implicate ILC2s as a direct link between skin barrier defects and early immune dysregulation in the skin.

Finally, although skin ILC2s could promote AD-like disease in the absence of adaptive immunity, they were also sufficient to drive adaptive T~H~2 cell responses *in vivo* ([@R21]). Recent studies show that this can occur indirectly through the effect of ILC2-derived IL-13 on DCs ([@R14]) and/or direct stimulation of T cells via MHC II ([@R27]). Further, ILC2s were visualized in the skin time employing intravital multiphoton microscopy and found to selectively interact with mast cells *in vivo* ([@R43]). Employing *in vitro* assays to monitor mast cell function, it has been proposed that ILC2s suppress mast cell function via the production of IL-13 in the steady state. In contrast, IL-2-mediated activation of ILC2s was sufficient to induce ILC2-dependent AD-like disease, enhanced production of IL-5 and the recruitment of eosinophils ([@R43]). Collectively, these studies demonstrated novel regulatory and proinflammatory functions of ILC2s in the skin.

ILC3s and Psoriasis {#S4}
===================

CD4^+^ T~H~17 cells that produce the effector cytokines IL-17 and IL-22 are classically believed to underlie the pathogenesis of psoriasis in humans ([@R37]). This T~H~17 cell-associated cytokine repertoire results in histologic features of regular acanthosis (uniform elongation of the epidermal rete ridges), parakeratosis (retention of nuclei in the stratum corneum) and a neutrophilic inflammatory infiltrate ([@R57]). However, Pantelyushin *et al.* employed a murine model of psoriasis-like disease and found that T~H~17 cells were not the dominant source of these cytokines but rather RORγt^+^ γδ T cells and ILC3s ([@R39]). In support of this, they demonstrated that lymphocyte-deficient mice develop psoriasiform inflammation in a similar manner to wild-type mice that harbor T~H~17 cells. Taken together, these findings provoked the hypothesis that IL-17- and IL-22-producing ILC3s may directly contribute to the pathogenesis of psoriasis-like disease. Indeed, loss-of-function studies employing ILC-deficient *Rag2^−/−^ γc^−/−^* mice demonstrated a reduction in disease severity ([@R39]). Collectively, these studies suggested that ILC3s may actually play a direct role in psoriasis in humans.

In support of the murine studies by Pantelyushin *et al.*, a more recent study identified the presence of IL-17- and IL-22-producing NKp44^+^ ILC3s in the blood and skin of psoriasis patients ([@R54]). Further investigation revealed that these NKp44^+^ ILC3s are highly enriched in both lesional and non-lesional skin of psoriasis patients in comparison to healthy control skin. These findings were confirmed by two separate studies demonstrating increased frequencies of RORγt^+^ CD56^+^ ILC3s that express NKG2D in both lesional and non-lesional skin of psoriasis patients ([@R8]) and NKp44^+^ ILC3s selectively enriched in lesional psoriasis skin ([@R52]). In support of a potential role for ILC3s in the pathogenesis of psoriasis, a case study in a patient on anti-tumor necrosis factor therapy (adalimumab) demonstrated correlation between therapeutic response and a reduction in ILC3s ([@R54]). Further, Teunissen *et al.* found that NKp44^−^ ILC3s convert to NKp44^+^ ILC3s following stimulation with IL-1β and IL-23 ([Figure 1](#F1){ref-type="fig"}). Given that disruption of the p40 subunit of IL-23 is an effective therapy (ustekinumab) for psoriasis, these findings implicate ILC3s as a potential mechanism by which IL-23 may mediate disease. Similar to skin ILC2s, ILC3s were also found to express the skin-homing marker CLA ([@R52]; [@R54]). Strikingly CLA expression was much higher on ILC3s in comparison to conventional CD4^+^ or CD8^+^ T cells ([@R54]). Collectively, homologous to ILC2s in AD, these studies highlight a potential role for skin ILC3s in the pathogenesis of psoriasis.

Prior studies on ILC3s have demonstrated diverse functions in the intestine ranging from maintenance of epithelial barrier function to inflammation and protective immunity to extracellular bacteria ([@R17]). Furthermore, ILC3s have been found to directly regulate the function of CD4^+^ T cells to promote tissue homeostasis in the intestine ([@R16]). Although ILC3s have been implicated as proinflammatory cells in psoriasis ([@R39]), whether they interact with adaptive CD4^+^ T cells or help to maintain tissue homeostasis in the skin remains to be determined.

ILC1s and Skin Inflammation {#S5}
===========================

ILC1s are not as well-defined as the ILC2 and ILC3 subsets. In addition to conventional NK (cNK) cells, multiple ILC1-like cells have been reported. Cytotoxic intestinal intraepithelial NKp44^+^ CD103^+^ (human) and CD160^+^ NKp46^+^ NK1.1^+^ (murine) ILC1-like cells resemble NK cells but are IL-15-independent and lack CD127 expression ([@R12]). More recently, non-cytotoxic T-bet^+^ Eomes^−^ CD127^+^ non-NK cell ILC1s, which arise from a distinct precursor that does not give rise to cNK cells, but are dependent on IL-15 for their maintenance and survival have been reported ([@R23]). Based on their distinctly non-NK cell lineage, these cells now appear to be bona fide ILC1s. Further, T-bet-expressing "ex-RORγt" ILC3s arise from RORγt^+^ precursors and can be instructed by IL-12 and/or commensal microbiota for their differentiation into IFN-γ-expressing NK receptor-expressing ILC1-like cells ([@R2]; [@R24]; [@R42]; [@R55]). Despite these differences, ILC1-like cells and ILC1s are similar in that all express T-bet and IFN-γ ([@R2]; [@R12]; [@R23]; [@R24]) ([Figure 1](#F1){ref-type="fig"}). They have also been shown to produce TNF-α and mediate immunity to intracellular infections with *Toxoplasma gondii* and *Salmonella* ([@R23]; [@R24]). In addition, human ILC1s are associated with Crohn's disease ([@R2]; [@R12]) and their murine counterpart has been shown to contribute to the development of experimental colitis ([@R12]). Although CRTH2^−^ c-Kit^−^ NKp44^−^ CD161^+^ ILC1s have been identified in human skin as a rare population ([@R52]; [@R54]), their function in skin disease remains unknown and is an exciting area of future inquiry. Recent studies have demonstrated that allergic contact dermatitis (ACD) can exhibit mixed T~H~ cell responses ([@R7]) in addition to classical T~H~1 cytokine responses ([@R13]; [@R19]; [@R20]; [@R44]). Similarly, based on the recent studies with ILC2s and ILC3s, it is possible that skin ILC1s may also contribute to the development of ACD.

Conclusions {#S6}
===========

The mammalian immune system has evolved a sophisticated array of adaptive immune responses to ward off invading microbial pathogens at the skin barrier. Specifically, adaptive immune cells such as T cells can recognize and combat infections in a specialized manner by recognizing specific antigens encountered over time. Additionally, recent studies have also demonstrated that adaptive T cells also limit the translocation of skin commensal bacteria into the lymphatic system ([@R47]). However, it is widely appreciated that inappropriate immune responses in the skin against environmental allergens or self-antigens can result in the development of a variety of inflammatory skin disorders. Therefore, interventions for diseases such as AD and psoriasis have classically attempted to target adaptive T cells.

The identification of different ILC populations that are resident at the skin barrier indicates that these cells may have evolved to respond immediately to pathogenic signals and to aid the adaptive immune system in mounting a robust immune response. The studies outlined in this review highlight that dysregulation of ILCs can result in the development of multiple inflammatory skin diseases. Although commensal microbiota in the gut are known to interact with ILC1-like cells ([@R24]; [@R55]) and ILC3s ([@R16]) ([@R41]; [@R50]), their interactions with ILC2s and their role in skin barrier homeostasis is less well defined. It would be expected that innate signals from skin commensal microbiota are required to maintain normal frequencies and functions of skin ILCs and this remains an exciting area of future investigation. More broadly, how ILCs are regulated in the skin, the array of effector mechanisms they employ and their potential role in maintaining skin barrier homeostasis remains unclear. Inflammatory skin diseases are the most common conditions affecting the skin and it is possible that ILCs will play critical roles in a variety of disease states including, but not limited to, ACD, bullous pemphigoid, arthropod bites and Sweet's syndrome. Based on the histopathology of these disease states it can be hypothesized which ILC subsets (e.g., ILC2s for eosinophilic or ILC3s for neutrophilic inflammation) may play a role in their pathogenesis. To improve our understanding of the function of skin ILCs, further investigation is necessary to (i) understand the contributions of ILC populations to different disease states, (ii) examine how ILCs regulate skin homeostasis and (iii) identify novel ILC-specific markers for therapeutic intervention. Studying the mechanisms that maintain skin immune homeostasis in health and disease may identify new therapeutic targets for the treatment of numerous chronic inflammatory skin diseases.
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![Regulation and function of human skin ILC responses\
Human skin ILC1s express CD161 and would be predicted to be activated by IL-12 and IL-15 and produce the effector cytokines TNF-α and IFN-γ. Human skin ILC2s express KLRG1, CLA, CCR4, IL-25R (IL-17Rb), IL-33R (ST2), CRTH2 and TSLPR. In response to IL-25, IL-33 and/or TSLP they produce effector cytokines IL-5 and IL-13 and have been implicated in atopic dermatitis. Human skin ILC2s also migrate in response to PGD~2~. Human skin ILC3s express NKp44 and CLA, produce IL-17 and IL-22 in response to IL-1β and IL-23 and have been implicated in psoriasis.](nihms626987f1){#F1}

![ILC2s and skin barrier dysfunction\
Human skin ILC2s have been implicated in the pathogenesis of atopic dermatitis and are activated by the epithelial cell-derived cytokines IL-25, IL-33 and/or TSLP to produce IL-5 and IL-13. In contrast, the keratinocyte cell adhesion molecule E-cadherin has been shown to inhibit the activation of skin ILC2s, possibly via KLRG1. Atopic dermatitis-associated inflammation and loss of skin barrier protein filaggrin expression is associated with the loss of E-cadherin expression in keratinocytes.](nihms626987f2){#F2}
